Publications by authors named "Gerard Barron"

Claim this Profile
I
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Bruce A C Cree, Jeffrey L Bennett, Ho Jin Kim, Brian G Weinshenker, Sean J Pittock, Gerard Barron

Lancet· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuromyelitis optica spectrum disorder: Patient experience and quality of life.
Janine Beekman, Aysha Keisler, Omar Pedraza, Masayuki Haramura, Athos Gianella-Borradori, Gerard Barron

Neurol Neuroimmunol Neuroinflamm· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.
Mark A Agius, Gabriela Klodowska-Duda, Maciej Maciejowski, Andrzej Potemkowski, Jing Li, Gerard Barron

Mult Scler· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Placebo-controlled study in neuromyelitis optica-Ethical and design considerations.
Bruce Ac Cree, Jeffrey L Bennett, Mark Sheehan, Jeffrey Cohen, Hans-Peter Hartung, Gerard Barron

Mult Scler· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and opportunities in designing clinical trials for neuromyelitis optica.
Brian G Weinshenker, Gerard Barron, Jacinta M Behne, Jeffery L Bennett, Peter S Chin

Neurology· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis